Climadinone® Uno (Klimadynon® Uno)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceCystic rhizome rhizome extractCystic rhizome rhizome extract
Similar drugsTo uncover
  • Climadinone®
    pills inwards 
    Bionoric CE     Germany
  • Climadinone®
    drops inwards 
    Bionoric CE     Germany
  • Climadinone® Uno
    pills inwards 
    Bionoric CE     Germany
  • Tsi-klim®
    drops inwards 
    EVALAR, CJSC     Russia
    • Dosage form: & nbspFilm-coated tablets.
    Composition:

    Composition (per 1 tablet)

    Active substances:

    Tsimitsifugi racemose * rhizome extract native dry (4,5-8,5: 1, extractant-ethanol 60 % in volume ratio) ** - 6.5 mg

    Excipients:

    core tablet:

    Cellulose - 6,350 mg

    Silicon dioxide colloid - 3,150 mg

    Lactose monohydrate - 19,000 mg

    Magnesium stearate - 2,500 mg

    Corn starch - 25,000 mg

    Calcium hydrogen phosphate dihydrate - 177,500 mg

    Carboxymethyl starch sodium - 10,000 mg

    tablet shell:

    Lactose monohydrate - 3.395 mg

    Hypromellose - 2,640 mg

    Macrogol-4000 - 0.943 mg

    Titanium dioxide - 2.452 mg

    Iron colorant red oxide - 0.230 mg

    Dye iron iron oxide - 0.340 mg

    * - Latin name - Cimicifuga racemosa L.

    ** - tsimitsifugi raceme rhizome extract dry standardized 32.5 mg contains cystic rhizomes rhizomes native dry - 20%, lactose monohydrate - 58.5%, cellulose - 19.5% and silicon colloidal dioxide - 2%.

    Description:

    Round biconvex tablets, covered with a film coating of pink color with a brown tinge, with a risk on one side.

    Pharmacotherapeutic group:An antimaliotic agent of plant origin.
    ATX: & nbsp

    G.02.C.X   Other drugs for use in gynecology

    Pharmacodynamics:

    Climadinone® Uno has an estrogen-like effect, exhibits sedative properties, has a positive therapeutic effect on the autonomic nervous system. The use of the drug contributes to the weakening or complete disappearance of the symptoms of malaise in the climacteric period.

    The therapeutic effect of Climadinone® Uno occurs gradually and manifests itself after about 2 weeks of treatment.

    Pharmacokinetics:
    Indications:Vegetovascular and psychiatric disorders in premenopausal and postmenopausal ("hot flashes", excessive sweating, sleep disturbance, increased excitability, mood changes, apathy, etc.).
    Contraindications:

    Individual hypersensitivity to the drug components, lactose intolerance, lactase deficiency, glucose-galactose malabsorption (due to the content of lactose in the preparation).

    Carefully:

    Violation of the function of the liver. Patients who have had previous liver disease before taking the drug should consult a doctor.

    Pregnancy and lactation:

    Do not use during pregnancy and lactation.

    Dosing and Administration:

    Climadinona® Uno is taken orally 1 tablet once a day with a small amount of liquid and, if possible, at the same time of the day (morning or evening). Without consulting a doctor, the drug should not be taken for more than 3 months.

    Side effects:

    In rare cases, temporary pain in the stomach, allergic reactions to the components of the drug are possible. There are isolated reports of toxic effects on the liver in preparations containing tsimitsifugu. If any of the above or other adverse reactions appear, you should cancel the drug and consult a doctor.

    Overdose:

    In case of an overdose of Climadinona® Uno, complaints of stomach pain indicated in the section "Side effects" may be more pronounced. In this case, stop taking the medication and consult a doctor.

    Interaction:Interactions with other drugs are currently unknown.
    Special instructions:

    The drug may be prescribed to patients with diabetes mellitus, since the bottom of the film-coated tablet contains 0.01 counted "bread units" (XE).

    In case of violation or resumption of menstruation, as well as with prolonged or other newly arising complaints, it is necessary to consult a doctor, as there may be a case of diseases requiring medical consultation.

    Without the recommendation of a doctor should not be used simultaneously with estogensoderzhaschimi drugs. If there are symptoms suggestive of liver damage (for example, fatigue, loss of appetite, yellowing of the skin and eyes, severe pain in the upper abdomen with nausea and vomiting, dark urine), stop taking the drug and consult a doctor.

    Patients who have been or are undergoing treatment for hormone-dependent tumors (particularly breast cancer) should not take the drug without consulting a doctor.

    Effect on the ability to drive transp. cf. and fur:

    When used in recommended doses, the drug does not affect the ability to drive vehicles and work with mechanisms.

    Form release / dosage:Film-coated tablets.
    Packaging:

    For 15 tablets in an aluminum foil blister (bottom side) and PVC / PE / PVDC film (upper side). For 2, 4, 6 blisters are placed in a folding cardboard box along with instruction for use.

    Storage conditions:

    Store in a dry, dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

    Shelf life:

    4 years.

    Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:LS-001972
    Date of registration:26.03.2012
    The owner of the registration certificate:Bionoric CEBionoric CE Germany
    Manufacturer: & nbsp
    Representation: & nbspBIONORIKA LLC BIONORIKA LLC Russia
    Information update date: & nbsp06.10.2015
    Illustrated instructions
      Instructions
      Up